4:05 AM
 | 
Oct 02, 2017
 |  BC Extra  |  Financial News

KSQ debuts with $76M funding

Editor's Note: This article was updated on Oct 02, 2017 at 12:23 PM PDT

CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and Alexandria Equities. The company said the funding is spread across a series A and B round but declined to break out...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >